Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Immunodiagnostic Systems Holdings PLC

4 Jun 2021 08:23

RNS Number : 8645A
ODDO BHF Asset Management SAS
04 June 2021
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

ODDO BHF Asset Management SAS

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

IMMUNODIAGNOSTIC SYSTEMS HOLDINGS PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

03/06/2021

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

2p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

688 735

2.39%

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

688 735

2.39%

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

2p ordinary

Purchase

15 000

375 GBp

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 (c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

04/06/2021

Contact name:

Sophie SABRI

 

+33 1 44 51 85 20

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETUSUBRAAUNRRR
Date   Source Headline
14th Dec 20127:00 amRNSDirectorate Change
12th Dec 20124:00 pmRNSHolding(s) in Company
12th Dec 20127:00 amRNSHolding(s) in Company
10th Dec 20126:08 pmRNSHolding(s) in Company
30th Nov 20126:15 pmRNSDirector/PDMR Shareholding
26th Nov 20127:00 amRNSHalf Yearly Report
24th Oct 201210:59 amRNSNotice of Results
19th Oct 20127:00 amRNSDirectorate Change Update
17th Oct 201211:41 amRNSSettlement on Escalon debt
1st Oct 201210:31 amRNSHolding(s) in Company
17th Sep 201212:54 pmRNSRedirectorate
14th Sep 20126:09 pmRNSAGM Result
14th Sep 20127:00 amRNSAGM Statement
15th Aug 20127:00 amRNSBoard Change
3rd Aug 20122:33 pmRNSDirector/PDMR Shareholding
30th Jul 201210:18 amRNSHolding(s) in Company
27th Jul 20129:29 amRNSHolding(s) in Company
27th Jul 20129:24 amRNSHolding(s) in Company
26th Jul 201210:30 amRNSAnnual Report and Accounts & Notice of AGM
2nd Jul 20127:00 amRNSDirectorate Change
25th Jun 20127:00 amRNSFinal Results
14th Jun 20127:00 amRNSProduct Launch
23rd Apr 201211:02 amRNSIDS Receives Prestigious Queens Award
12th Apr 20127:00 amRNSTrading Statement
4th Apr 20129:56 amRNSHolding(s) in Company
4th Apr 20127:00 amRNS1,25-Dihydroxy Vitamin D Assay Launch
14th Feb 20127:00 amRNSFDA clearance for a new specialist assay
9th Feb 20127:00 amRNSChange of Adviser
1st Feb 20123:16 pmRNSChange of Adviser
30th Jan 20128:27 amRNSDirector/PDMR Shareholding - Replacement
30th Jan 20127:00 amRNSDirector/PDMR Shareholding
30th Jan 20127:00 amRNSDirector/PDMR Shareholding
27th Jan 20127:00 amRNSDirector/PDMR Shareholding
24th Jan 20123:18 pmRNSHolding(s) in Company
24th Jan 20122:38 pmRNSHolding(s) in Company
23rd Jan 20127:01 amRNSTrading update
12th Jan 201212:13 pmRNSHolding(s) in Company
15th Dec 201111:02 amRNSHolding(s) in Company
30th Nov 20115:23 pmRNSTotal Voting Rights
28th Nov 20117:00 amRNSInterim Results
14th Nov 20112:03 pmRNSIssue of Equity
6th Oct 20117:00 amRNSTrading Update
4th Oct 20112:45 pmRNSHolding(s) in Company
8th Sep 20115:22 pmRNSResult of AGM
8th Sep 20117:00 amRNSAGM Statement
31st Aug 20114:35 pmRNSPrice Monitoring Extension
30th Aug 20117:00 amRNSDirectorate Change
25th Jul 20117:00 amRNSDirectorate Change
29th Jun 20114:50 pmRNSExercise of Options & Total Voting Rights
27th Jun 20117:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.